Lumida
/WAT
⌘K
Waters Corp

Waters Corp

WAT
$408.34USD↑+1.67%+6.70 today

MARKET CAP

40.1B

P/E (TTM)

29.4x

FWD P/E

25.5x

DAY RANGE

$404 – $410

52W RANGE

$283
$426

AI Summary

Stalk
StalkMedium

WAT is undergoing a Stage 2 corrective pullback within its long-term uptrend, consolidating near the 9/20 EMAs after finding support at the 50-day SMA. Momentum and RSI readings are neutral, offering no clear timing edge, while medium-term asymmetry remains bullish with no active patterns. Execution is deferred—await a reclaim and acceptance above the short-term EMAs or a stabilizing bounce off the 50-day SMA before engaging.

  • ↑Q2 revenue reached $1.645 B (+7% organic YoY) and EPS hit $3.05 (+3%).
  • ↑Raised 2026 guidance to 7–9% organic constant-currency growth and $14.45–14.65 EPS.
  • ↓Negative growth factor signals challenges sustaining revenue expansion.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Waters Corporation (NYSE: WAT) is a leading player in the biotechnology and analytical instruments sectors, specializing in advanced analytical technologies for laboratories engaged in life sciences, pharmaceuticals, and materials sciences. The company is strategically positioned within the growth of precision medicine and life sciences, bolstered by its recent acquisition of Becton Dickinson & Company's Biosciences and Diagnostic Solutions. This enhances Waters' market presence and offers robust potential for future revenue growth.

Bull says

  • ↑Q2 revenue reached $1.645 B (+7% organic YoY) and EPS hit $3.05 (+3%).
  • ↑Raised 2026 guidance to 7–9% organic constant-currency growth and $14.45–14.65 EPS.
  • ↑Launched Xevo TQ Absolute XR and PacTech FXI, detecting infections up to 3 hours faster.
  • ↑Targeting $75 M cumulative cost savings in 2026 to improve margins.
  • ↑Pharma recovery and China relocalization underpin $6.42–6.48 B revenue outlook.
  • ↑Valuation attractive: high earnings yield, strong book-to-price, positive analyst revisions.

Bear says

  • ↓Negative growth factor signals challenges sustaining revenue expansion.
  • ↓China organic revenue down amid DRG headwinds.
  • ↓USD strength shaved ~$0.25 off EPS, pressuring profitability.
  • ↓High volatility and negative institutional sentiment suggest investor caution.
  • ↓Integration risks from BD Biosciences deal could strain execution.
  • ↓Tariffs and cost cuts risk margin compression; dividend yield remains low.

Investment themes with WAT

Quality↓ -0.56%

Companies with strong fundamentals and stability

NVDA · AAPL · MSFT

Earnings Call · Q4 2023 · Mgmt. Guidance

Updated 02-13-2025neutral

Transcript signals

Bull points

  • we expect that, in the first half of the year, we'll see similar trends that we saw in the second half of the year in LC. And the second half of the year, we will start to see a bit of a relief and growth.
  • we're starting to see biotechs start to spend again, we're starting to see CDMOs, especially recurring revenue, come back. And in branded generics, more and more hospitals are opening up.
  • Throughout the year, our teams kept an unwavering focus on customers, launched innovative new products, and delivered strong business performance, all during highly eventful times with dynamic market conditions.

Bear points

  • LC overall declined almost 10%, 11%. And bulk of that decline came from China. So, China declined roughly 30%, 40% – maybe actually close to 40%, 45% in LC.
  • In the fourth quarter, sales declined 4.5% as reported, which was in line with our expectations.
  • For the full year, sales declined 0.5% as reported and 2% in organic constant currency.
Read full transcript analysis ›